Elayta Shows Potential for Improving Brain Cell Activity in Alzheimer’s, Trial Results Show

Elayta Shows Potential for Improving Brain Cell Activity in Alzheimer’s, Trial Results Show
Cognition Therapeutics' lead investigative therapy Elayta (CT1812) shows promise in improving the activity of brain cells in patients with Alzheimer's disease, according to the results of a Phase 1b/2a trial. Elayta is a small molecule that displaces amyloid-beta oligomers formed in Alzheimer’s disease from their binding sites, or receptors, on nerve cells in the brain. Preclinical data showed that treatment with this therapy can stop memory loss in animal models of Alzheimer’s. The Phase 1b/2a trial (NCT02907567
Subscribe or to access all post and page content.